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Diabetic nephropathy, the leading cause of end-stage 
renal disease worldwide, is characterized pathologically by 
cellular hypertrophy and increased extracellular matrix 
accumulation, and clinically by proteinuria. The molecular 
and cellular mechanisms responsible for these charac-
teristics have not been completely resolved. Although the 
diabetic milieu, hemodynamic changes, and local growth 
factors are considered to be mediators in the pathogenesis 
of diabetic nephropathy, the underlying pathways are not 
well understood.
Numerous recent studies have demonstrated the infil-
tration of inflammatory cells within renal glomeruli and 
the tubulointerstitium in both human diabetic patients 
and experimental diabetic animals. Monocytes/macro-
phages are the principle inflammatory cells present in the 
diabetic kidney, and accumulating evidence suggests that 
monocytes/macrophages are important in the develop-
ment and progression of glomerular and tubulointerstitial 
lesions in diabetic nephropathy [1]. Strict control of blood 
glucose and blood pressure levels along with the use of 
renin-angiotensin system blockers has been the gold 
standard for the management of diabetic patients. The 
administration of anti-inflammatory agents such as my-
cophenolate mofetil and retinoic acid was recently found 
to reduce inflammatory cell infiltration and prevent renal 
injury in experimental diabetic animals [2]. Irradiation 
also had a beneficial effect on diabetic nephropathy via 
an anti-inflammatory mechanism. These findings suggest 
that an inflammatory process may also contribute to the 
pathogenesis of diabetic nephropathy and that drugs with 
anti-inflammatory effects may be useful in preventing ne-
phropathy in diabetic patients.
Pentoxifylline (PTX) is one of a number of anti-inflam-
matory drugs that have been used for clinical trials in dia-
betic patients with nephropathy. PTX, a nonselective in-
hibitor of cyclic-3', 5'-nucleotide phosphodiesterase (PDE), 
has been shown to improve circulation by altering red 
blood cell deformability, improving capillary microcircula-
tion, and acting as an adenosine antagonist [3]. Clinically, 
it has been used mainly to treat patients with peripheral 
vascular disease. Recently, mounting evidence has dem-
onstrated diverse anti-inflammatory, antiproliferative, 
and antifibrotic functions for PTX. It has been shown 
to inhibit not only the transcription of tumor necrosis 
factor-α (TNF-α) and transforming growth factor-β1 genes 
but also the proliferation of lymphocytes, fibroblasts, and 
mesangial cells, leading to reduced extracellular matrix 
synthesis. In addition, proteinuria, glomerular sclerosis, 
interstitial inflammation, and apoptosis were ameliorated 
by PTX administration in animals with various kidney 
diseases, including anti-Thy1 nephritis, remnant kidney, 
crescentic glomerulonephritis, adriamycin-induced ne-
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phropathy, and diabetic nephropathy [4]. Considering 
these experimental findings and the potential of PTX 
to decrease intraglomerular pressure, PTX has been of 
interest as a therapeutic agent in patients with various 
kidney diseases. Previous studies have demonstrated that 
PTX significantly decreased serum and urinary TNF-α 
levels in diabetic patients with nephropathy. Moreover, 
PTX treatment significantly attenuated the increase in 
urinary monocyte chemoattractant protein-1 concentra-
tions, which was associated with a significant decrease 
in urinary protein excretion, in patients with proteinuric 
primary glomerular diseases [5]. The renoprotective and 
anti-proteinuric effects of PTX have been considered to be 
attributed to its ability to downregulate the production of 
proinflammatory cytokines.
In the manuscript titled “Phosphodiesterase inhibitor 
improves renal tubulointerstitial hypoxia of diabetic rat 
kidney,” Sun et al. [6] investigated the effect of PTX in 
diabetic nephropathy from a different point of view. Based 
on the concept that chronic hypoxia, which is attributed 
to structural abnormalities and functional disorders of 
the renal vasculature, may play a role in the develop-
ment of tubulointerstitial fibrosis and atrophy in diabetic 
nephropathy, the authors hypothesized that PTX, a PDE 
inhibitor, could improve renal tubular hypoxia and the 
consequent renal injury in streptozotocin (STZ)-induced 
diabetic rats. The results of their study showed that the 
increase in protein-to-creatinine ratios in 8-week diabetic 
rats was significantly abrogated by PTX treatment. PTX 
also significantly ameliorated the increases in renal corti-
cal expression of hypoxia-inducible factor-1α (HIF-1α) 
and vascular endothelial growth factor mRNA in 8-week 
diabetic rats. In normal rat kidney cells, in contrast, HIF-
1α expression induced by CoCl2 (to create hypoxia in vitro) 
or by high glucose was not altered by PTX. The authors 
suggested that the underlying mechanism of the beneficial 
impact of PTX in diabetic nephropathy may be related to 
improved renal blood flow partly via the attenuation of 
peritubular endothelial dysfunction, rather than a direct 
effect on renal tubular cells.
The maintenance of both normal renal blood perfusion 
and oxygenation is critical for controlling renal func-
tion. Oxygen tension (pO2) is low in the renal medulla 
because of countercurrent oxygen diffusion between the 
descending and ascending vasa recta and the high rate of 
ion transport activity in the thick ascending limb of the 
loop of Henle. Therefore, the renal medulla is especially 
susceptible to further decreases in pO2. Renal hypoxia 
has been implicated in the pathogenesis of ischemic ne-
phropathy, and recent studies have suggested that it may 
participate in the development and progression of diabetic 
nephropathy via at least two major mechanisms: func-
tional hypoxia, which may occur as a result of increased 
oxygen consumption to support sodium reabsorption dur-
ing the early hyperfiltration stage of diabetic nephropathy, 
and oxidative stress-associated hypoxia, which is domi-
nant in later stages of diabetic nephropathy. In addition, 
diabetes is commonly associated with decreased bioavail-
ability of nitric oxide (NO), a potent regulator of vascular 
tone and oxygen utilization, and reduced renomedullary 
oxygen availability. Palm et al. [7] recently clarified the 
interrelationship between reduced NO bioavailability and 
hypoxia in the renal medulla in 2-week STZ-induced dia-
betic rats. In that study, L-arginine, but not α-tocopherol, 
significantly abrogated the decrease in renomedullary NO 
levels in diabetic rats. In contrast, reduced medullary pO2 
in diabetic rats was ameliorated by either acute arginine 
administration or long-term antioxidant treatment, ir-
respective of comparable intrarenal microcirculation in 
control rats. These findings established a link between NO 
synthase substrate availability and the changes in medul-
lary pO2 accompanying diabetes. Similarly, blood oxygen 
level-dependent magnetic resonance imaging revealed hy-
poxic changes in the renal medulla as early as 2 days after 
STZ-induction of diabetes, while there was no significant 
difference in renal medullary blood flow between diabetic 
and control rats [8]. Given these findings and the fact that 
NO, which is synthesized from L-arginine and exerts its 
action in part via cGMP, which is rapidly hydrolyzed and 
degraded by PDE, inhibitors of PDE may have beneficial 
effects on the kidney.
In fact, a previous study by Han et al. [9] of the current 
paper found that the administration of PTX inhibited the 
renal inflammatory reaction at 4 weeks and prevented 
proteinuria at 8 weeks in STZ-induced diabetic rats, sug-
gesting that prolonged administration of PTX enhanced 
its protective effects. However, the current study focused 
on the effect of PTX on renal hypoxia. Collectively, it is 
surmised that PTX, a PDE inhibitor, can attenuate renal 
hypoxia in diabetic rats by restoring the decreased NO 
bioavailability, with or without changes in renal medul-
lary blood flow. Nevertheless, the results of a recent meta-
analysis on the effect of PTX on proteinuria in diabetic 
patients were disappointing [10], as PTX appeared to have http://dx.doi.org/10.3904/kjim.2012.27.2.151 http://www.kjim.or.kr
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effects similar to those of captopril in terms of reducing 
proteinuria. A secondary analysis showed that patients 
with microalbuminuria had no significant decrease in uri-
nary protein excretion upon PTX treatment, whereas PTX 
significantly reduced the amount of proteinuria in patients 
with overt proteinuria. Additional large, high-quality stud-
ies are required to elucidate the beneficial renoprotective 
effect and underlying mechanism of PTX in patients with 
diabetic nephropathy.
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